AstraZeneca Gets Positive Results From Phase 3 Trial of Eplontersen
21 Junho 2022 - 3:47AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that Eplontersen met co-primary and
secondary endpoints in a phase 3 trial for hereditary
transthyretin-mediated amyloid polyneuropathy.
The pharmaceutical company said that it got positive results
from the trial and that eplontersen reached a statistically
significant and clinically meaningful change from baseline for its
co-primary endpoint of percent change in serum transthyretin
concentration, reducing serum transthyretin protein production.
Eplontersen also reached its co-primary endpoint of change from
baseline in the modified Neuropathy Impairment Score +7 versus
external placebo group.
Eplontersen will be jointly developed and commercialized with
Ionis in the U.S. and developed and commercialized in the rest of
the world by AstraZeneca.
The filing of a new drug application for eplontersen with the
U.S. Food & Drug Administration is expected in 2022.
Hereditary transthyretin-mediated amyloid polyneuropathy is a
disease that leads to nerve damage with motor disability within
five years of diagnosis and, without treatment, can be fatal within
10 years.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
June 21, 2022 02:32 ET (06:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
